PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annu...(nsfused in ESA-treated patients to the n...),Health

units that would be transfused if ESAs were discontinued or limited in

the same population.

Data on PROCRIT Investigational Extended Dosing Regimens

-- Abstract: Early vs. Standard Intervention With an Extended Epoetin alfa

(EPO) Dose Regimen of 120,000 Units (U) Every 3 Weeks (Q3W) in

Chemotherapy (CT)-Induced Anemia: Results for Elderly vs. Younger

Patients in a Randomized Clinical Trial

Veena Charu, M.D., Pacific Cancer Medical Center, Inc., Anaheim, CA

Publication Number 3769

A retrospective subset analysis of a prospective, randomized, open-

label, multi-center study compared key efficacy and safety results of

elderly (n=62) and younger (n=73) patients with non-myeloid malignancy.

Patients with chemotherapy planned for greater than or equal to 9 weeks

and baseline hemoglobin greater than or equal to 11 and less than or

equal to 12 grams per deciliter (g/dL) were randomized either to

"early" intervention with Epoetin alfa or to "standard" intervention

with Epoetin alfa when hemoglobin decreased to <11 g/dL.

-- Abstract: Erythroid Response to Epoetin alfa (EPO) 120,000 Units (U)

Every Three Weeks (Q3W) Initiated Early or at a Standard Threshold in

Chemotherapy-Induced Anemia (CIA)

Veena Charu, M.D., Pacific Cancer Medical Center, Inc., Anaheim, CA

Publication Number 3770

A retrospective analysis of observed hematologic profiles from a 16-

week, open-label, randomized study enrolled patients with non-myeloid

malignancy, baseline hemoglobin greater than or equal to 11 and less

than or equal to 12 g/dL, and chemotherapy planned for greater than or

equal to 9 weeks to evaluate whether hemoglobin levels could be

adequately maintained with Q3W Epoetin alfa init
'/>"/>